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Summary: Clinically used antiepileptic drugs (AEDs) de- 
crease membrane excitability by interacting with ion channels 
or neurotransmitter receptors. Currently available AEDs ap- 
pear to act on sodium channels, GABAA receptors, or calcium 
channels. Phenytoin, carbamazepine, and possibly valproate 
(VPA) decrease high-frequency repetitive firing of action po- 
tentials by enhancing sodium channel inactivation. Benzo- 
diazepines and barbiturates enhance GABAA receptor- 
mediated inhibition. Ethosuximide and possibly VPA reduce 
a low-threshold calcium current. The mechanisms of action 
of AEDs currently under development are less clear. Lamo- 
trigine may decrease sustained high-frequency repetitive 
firing. The mechanisms of action of felbamate are unknown. 
Gabapentin (GBP) appears to bind to a specific binding site 
in the central nervous system with a restricted regional 
distribution, but the identity of the binding site and the 
mechanism of action of GBP remain uncertain. Key Words: 
Anticonvulsants- Neuropharmacology - Neurotransmitten- 




A limited number of antiepileptic drugs (AEDs) are 
available for use in the treatment of patients with epi- 
lepsy. In the United States, AEDs are limited primarily 
to phenytoin (PHT), carbamazepine (CBZ), barbitu- 
rates and primidone (PRM), benzodiazepines (BZDs), 
valproate (VPA), and ethosuximide (ESM). Three ad- 
ditional AEDs may be available in the United States 
in the near future: felbamate (FBM), gabapentin (GBP), 
and lamotrigine (LTG). It is likely that the currently 
used AEDs as well as the new AEDs have as their pri- 
mary targets of action neurotransmitter receptors or 
ion channels. Three primary neurotransmitter receptor 
or ion channels are targeted by the currently prescribed 
AEDs and at least one of the newly developed 
ones: voltage-dependent sodium channels, voltage- 
dependent calcium channels, and GABAA receptor 
channels. Basic actions at these ion channels or neu- 
rotransmitter receptor channels may be responsible for 
the clinical actions bf those AEDs. The interaction of 
clinically available AEDs and the three new AEDs 
FBM, GBP, and LTG with those specific neurotrans- 
mitter receptors or ion channels will be the subject of 
this review. 
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PHENYTOIN AND CARBAMAZEPINE 
PHT and CBZ have been shown to interact with 
sodium channels at concentrations found free in the 
plasma of patients being treated for epilepsy (Macdon- 
ald, 1989). These AEDs were shown to reduce the fre- 
quency of sustained repetitive firing of action potentials 
in neurons in cell culture (McLean and Macdonald, 
1983, 1986b). The characteristic property of these 
AEDs was that they did not reduce the amplitude or 
duration of single action potentials but reduced the 
ability of neurons to fire trains of action potentials at 
high frequency. The limitation of high frequency re- 
petitive firing was voltage-dependent, limitation of fir- 
ing being increased after depolarization and reduced 
after hyperpolarization. Once developed, the limitation 
of firing was prolonged, lasting several hundred milli- 
seconds. The action of the AEDs appeared to be due 
to a shift of sodium channels to an inactive state that 
was similar to the normally occumng inactive state 
but from which recovery was delayed. 
The actions of PHT and CBZ on mammalian my- 
elinated nerve fibers have been studied (Schwarz and 
Grigat, 1989). Both AEDs produced a voltage- 
dependent block of sodium channels that could be re- 
moved by hyperpolarization. PHT produced a shift of 
the steady-state sodium channel inactivation curve to 
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more negative voltages. Both PHT and CBZ reduced 
the rate of recovery of sodium channels from inacti- 
vation. In control solutions, sodium channels recovered 
from complete inactivation within a few milliseconds 
after 500-ms depolarization to 25 mV. In the presence 
of 100 pM PHT, recovery was prolonged to 90 ms. 
With 100 pM CBZ, recovery was prolonged to 40 ms. 
At 50 pM, PHT and CBZ each produced a frequency- 
dependent block. At 50 pM, PHT produced an initial 
block of 50%. With repetitive stimulation at 10 Hz, 
the block increased to approximately 80% over 2.5 s. 
Recovery from that block required approximately 
2.5 s. At 100 pM. CBZ also produced a frequency- 
dependent block that was somewhat less pronounced 
than that produced by PHT. Thus, PHT and CBZ pro- 
duced voltage- and frequency-dependent block of so- 
dium channels. Because the concentration-response 
curves could be fitted assuming a first-order reaction, 
it was suggested that one drug molecule binds to one 
receptor near or at the sodium channel. The data also 
are consistent with PHT and CBZ binding with higher 
affinity to inactivated sodium channels rather than to 
open or resting sodium channels. Of interest was the 
finding that PHT had a longer time dependence for 
frequency-dependent block and for recovery from 
block than did CBZ. This difference would result in a 
more pronounced frequency-dependent block for PHT 
than for CBZ. Thus, although PHT and CBZ have 
quulitutivcly similar actions on sodium channels, the 
actions are quuntitutivcly somewhat different. That fact 
may explain, at least in part, differences in the efficacy 
of the two AEDs among patients. 
Similar voltage-clamp experiments were performed 
on isolated mammalian brain neurons (Wakamori et 
al., 1989). Hippocampal pyramidal neurons from the 
CA 1 region were obtained from 1 - and 2-week-old rats. 
PHT at 200 pM produced a 20-mV negative shift in 
the steady-state inactivation curve for sodium channels 
and produced frequency-dependent block of sodium 
channels. Frequency-dependent block was shown at 
frequencies as low as 1 Hz, and the block increased to 
50% at 10 Hz. Thus, the ability of PHT to enhance 
inactivation in neurons in cell culture and in mam- 
malian myelinated nerve fibers also was present in iso- 
lated mammalian neurons. 
The effect of PHT on human sodium channels also 
has been examined (Tomaselli et al., 1989). Total 
mRNA was extracted from human brain and injected 
into Xenopus oocytes. The human brain sodium chan- 
nels expressed in oocytes also were blocked by PHT in 
a voltage-, frequency-, and time-dependent fashion. 
The effects of PHT on human sodium channels were 
very similar to those on cultured mouse neurons, rat 
myelinated nerve, and rat hippocampal pyramidal 
neurons. 
Thus, evidence from voltage-clamp experiments has 
confirmed the basic mechanism of action of PHT and 
CBZ. Both AEDs appear to stabilize the inactive form 
of the sodium channel in a voltage-dependent fashion, 
the effect being lessened at large negative membrane 
potentials and increased at less-negative membrane 
potentials. Both AEDs slow the rate of recovery from 
sodium channel inactivation and shift the steady-state 
sodium inactivation curve to more negative voltages. 
That stabilization of the inactive form of the receptor 
results in frequency-dependent block of sodium chan- 
nels and blockade of sustained high-frequency repeti- 
tive firing of action potentials evoked from reduced 
membrane potentials. Of interest is the finding that 
PHT has a stronger slowing effect than CBZ, which 
would result in slightly different actions of those AEDs 
under different conditions of repetitive firing. 
ETHOSUXIMIDE AND TRIMETHADIONE 
A number of AEDs have been demonstrated to 
modify the properties of voltage-dependent calcium 
channels (Macdonald, 1989). PHT, barbiturates, and 
BZDs reduce calcium influx into synaptic terminals 
and block presynaptic release of neurotransmitter. 
However, those actions have been demonstrated only 
at high drug concentrations that are above therapeutic 
free serum concentrations. Thus, it has been concluded 
that AEDs do not have their primary actions on cal- 
cium channels. However, it has been shown that cal- 
cium channels are heterogeneous. In primary afferent 
neurons, at least four different types of channels have 
been described (Nowycky et al., 1985; Mintz et al., 
1992). These channels have been called L channels, T 
channels, N channels, and P channels. These channel 
types have different voltage ranges for activation and 
inactivation and different rates of activation and in- 
activation. It also is likely that these are not the only 
types of calcium channels present on neurons. The 
finding that neurons express multiple calcium channels 
suggests that AEDs may act on specific subtypes of 
channels. This fact has been demonstrated for the 
AEDs ESM, trimethadione (TMO), and VPA, which 
are effective in the treatment of generalized absence 
seizures. 
Generalized absence epilepsy is characterized clini- 
cally by brief periods of loss of consciousness and elec- 
trically by generalized 3-Hz spike and wave EEG dis- 
charges. It has been suggested that thalamic relay 
neurons play a critical role in the generation of the 
abnormal thalamocortical rhythmicity that underlies 
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the 3-Hz spike and wave discharge. Whole-cell voltage- 
clamp recordings from acutely dissociated relay neu- 
rons from the rat thalamus have demonstrated the 
presence of low-threshold (T-type) and high-threshold 
calcium currents (Coulter et al., 1989~).  The low- 
threshold T currents had properties such that T channel 
activation was necessary and sufficient to cause the 
generation of low-threshold calcium spikes in thalamic 
relay neurons. It was shown that both ESM and di- 
methadione (DMO), the active metabolite of TMO, 
reduced the T-type calcium current of thalamic neu- 
rons isolated from guinea pigs or rats (Coulter et al., 
19896,~). The reduction of the T-type current was pro- 
duced at concentrations of ESM and DMO that have 
clinical relevance. PHT and CBZ, which are ineffective 
in the control of generalizeki absence seizures, had 
minimal effects on the T-type calcium current. The 
ESM-induced reduction of the T-type current was 
voltage dependent. The reduction was most prominent 
at negative membrane potentials and less prominent 
at more positive membrane potentials. ESM did not 
alter the voltage dependency of steady-state inactivation 
or the time course of recovery from inactivation. DMO 
reduced the T-type calcium current by a mechanism 
similar to that of ESM. Another anticonvulsant suc- 
cinimide, a-methyl-a-phenylsuccinimide, also reduced 
T-type calcium currents, whereas a convulsant succin- 
imide, tetramethylsuccinimide, reduced the T-type 
calcium current only at very high concentrations 
(Coulter et al., 1990). These results suggest that anti- 
convulsant succinimides and DMO, compounds that 
are effective in the treatment of generalized absence 
epilepsy, may exert their primary action by reducing 
the low-threshold or T-type calcium current in thalamic 
relay neurons. 
BENZODIAZEPINES AND BARBITURATES 
The y-aminobutyric acid, (GABAA) receptor is a 
macromolecular protein containing binding sites for 
at least GABA, picrotoxin, neurosteroids, barbiturates 
and BZDs, and a chloride ion-selective channel 
(DeLorey and Olsen, 1992). The receptor appears to 
be composed of combinations of different isoforms of 
a, p, y, 6, and p polypeptide subunits (Schofield et al., 
1987; Pritchett et al., 1989~;  Shivers et al., 1989; Cut- 
ting et al., I99 1). GABAA receptors composed of only 
a and fl subunits form chloride channels that are an- 
tagonized by picrotoxin and have an increased response 
in the presence of pentobarbital but lack sensitivity to 
BZDs; the presence of a y subunit in addition to other 
subunits is necessary for full GABAA receptor phar- 
macology (Pritchett et al., 1989b). The subunit com- 
binations that are expressed in vivo are uncertain. 
GABA binds to GABAA receptors to regulate gating 
(opening and closing) of the chloride ion channel. The 
single-channel-gating properties of the main conduc- 
tance state of the native GABAA receptor in murine 
spinal cord neurons in culture have been characterized 
(Macdonald et al., 1989~;  Weiss and Magleby, 1989; 
Twyman et al., 1990). Binding of GABA increases the 
probability of channel opening, and the open channel 
can close and rapidly reopen to create bursts of open- 
ings. To explain this complex gating behavior, inves- 
tigators have modeled the single-channel activity of the 
main conductance state using a reaction scheme in- 
corporating 2 sequential GABA binding sites, 3 open 
states, and 10 closed states (Macdonald et al., 1989~;  
Twyman et al., 1990). 
Barbiturate and BZD drugs can modulate the 
GABAA receptor current by regulating the single- 
channel properties of the receptor. To enhance the 
current, a drug may increase the channel conductance, 
increase the channel open-and-burst frequencies, and/ 
or increase the channel open-and-burst durations. The 
kinetic model of the GABAA receptor has been used 
to study the mechanisms of action of AEDs that act 
through the GABAA receptor. 
Barbiturates enhance the GABAA receptor current 
by binding to an allosteric regulatory site on the re- 
ceptor (Olsen, 1987). Results from fluctuation analysis 
suggest that phenobarbital (PB) and pentobarbital in- 
creased the mean channel open duration of GABAA 
receptor currents without altering channel conductance 
(Study and Barker, 198 I ) .  Single-channel recordings 
of barbiturate-enhanced single GABAA receptor cur- 
rents directly demonstrate that barbiturates increase 
mean channel open duration but do not alter receptor 
conductance or opening frequency (Macdonald et al., 
1989b; Twyman et al., 1989). 
For a l p I  receptors expressed in Xenopus oocytes or 
Chinese hamster ovary (CHO) cells, currents were in- 
creased by pentobarbital (Moss et al., 1990; Verdoorn 
et al., 1990). Furthermore, the concentration depen- 
dence for the effect was the same for receptors with 
different a and p subunits coexpressed with y2 and 
with p2y2 alone in Xenopus oocytes (Verdoorn et al., 
1990). These results directly demonstrate that the a 
and p subunits contain the allosteric regulatory site for 
barbiturates. 
GABAA receptors have a high-affinity binding site 
for BZDs, and BZD- and GABAA receptor-binding 
sites have been demonstrated to be coupled allosteri- 
cally (Olsen, 1987). BZDs increase GABAA receptor 
current. Results from fluctuation analysis suggest that 
the BZD diazepam increases GABAA receptor current 
by increasing opening frequency without altering 
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channel conductance or open duration (Study and 
Barker, 198 I) .  Single-channel recordings have con- 
firmed that BZDs increase receptor opening frequency 
without altering mean open time or conductance (Vi- 
cini et al., 1987; Rogers et al., 1989). 
GABAA receptors expressed in Xenopzis oocytes and 
CHO cells formed from a lp I  subunits are insensitive to 
BZDs (Pritchett et al., 19896; Moss et al., 1990). The 
basis for this insensitivity wasdetermined when two forms 
of a third GABAA receptor subunit, the yI and y2 sub- 
units, were isolated from a human fetal brain cDNA 
library (Pritchett et al., 39896). When the y2 subunit 
was coexpressed transiently with aI and PI  subunits 
in human embryonic kidney cells, fully functional 
GABAA receptors were formed that were sensitive to 
BZDs, (3-carbolines, barbiturates, and picrotoxin. 
Benzodiazepine receptors are heterogeneous, with 
BZDI and BZDII receptors having been characterized 
(Klepner et al., 1978). The identification of the three 
specific subunits forming GABAA receptors led to clar- 
ification of the basis for this heterogeneity. Expression 
of alP,y2 GABAA receptors in human kidney cells 
produces receptors similar to BZDI receptors, whereas 
expression of a2PIy2 and a3Ply2 GABAA receptors 
produces receptors similar to BZDII receptors (Pritchett 
et al., 1989~).  Thus, despite the finding that the y sub- 
unit confers benzodiazepine sensitivity to GABAA re- 
ceptors, the CY subunit appears to determine the type 
of BZD receptor expressed. BZDII receptors are also 
heterogeneous, being formed from a2Ply2 or a3P1y2 
subunit combinations. The physiological and phar- 
macological significance of the differential expression 
of CY subunits remains to be determined. 
VALPROATE 
The effect of VPA on sodium channels has been 
studied less extensively. It remains uncertain whether 
VPA has the same mechanism of action as PHT and 
CBZ. Although VPA blocked sustained high-frequency 
repetitive firing of neurons in culture (McLean and 
Macdonald, I986a), detailed voltage-clamp experi- 
ments on VPA actions on sodium currents have not 
been performed. It cannot be determined whether VPA 
has a mechanism of action similar to that of PHT and 
CBZ until these studies have been performed. 
VPA is one of the most effective drugs against gen- 
eralized absence seizures. Interestingly, initial studies 
of VPA did not demonstrate any effect on the low- 
threshold calcium current. A later study, however, 
demonstrated that VPA reduced T-type calcium cur- 
rents in primary afferent neurons (Kelly et al., 1990). 
The effect was produced over a concentration range of 
100-1,000 pM. However, the magnitude of the effect 
was modest, with a 16% reduction seen at 1,000 p M  
VPA. Whether this modest reduction in T-type calcium 
current is sufficient to explain the effect of VPA on 
generalized absence seizures is unclear. Furthermore, 
the basis for the discrepancy between the results ob- 
tained in rat thalamic neurons and those obtained in 
rat primary afferent neurons remains uncertain. It may 
be that different cell types have different sensitivities 
to those drugs or that the small effect is difficult to 
characterize. Whether this is a relevant mechanism of 
action for VPA remains to be determined. 
FELBAMATE 
FBM, 2-phenyl- I ,3-propanediol dicarbamate, is a 
dicarbamate that has a structure similar to meprobam- 
ate, an antianxiety agent. In experimental animals, 
FBM was effective in blocking seizures induced by 
maximal electroshock, pentylenetetrazol, and picro- 
toxin (Swinyard et al., 1986). FBM inhibited bicucul- 
line-induced seizures at high concentrations but was 
ineffective against strychnine-induced seizures (Sofia 
et al., 1991). These results suggest that FBM can both 
increase seizure threshold and prevent the electrical 
spread of seizure activity (Swinyard et al., 1986). In 
clinical studies, FBM has been effective against complex 
partial seizures in adults and the Lennox-Gastaut syn- 
drome in children. 
FBM has been tested for interaction with the GABAA 
receptor complex, a possible mechanism of its anti- 
convulsant activity. In rat brain cortical membranes, 
FBM did not affect ligand binding to the GABA-, 
BZD-, or picrotoxin-binding sites of the GABAA re- 
ceptor complex. In addition, in radiolabeled CI- influx 
studies in cultured mouse spinal cord neurons, FBM 
did not affect GABA-induced 36C1- influx (Ticku et al., 
199 I ) .  These results suggest that FBM may not have 
a direct effect on the GABAA receptor complex. How- 
ever, FBM in subprotective doses enhanced the pro- 
tective effects of DZP against seizures induced by max- 
imal electroshock, pentylenetetrazol, and isoniazid but 
not by bicuculline, suggesting that FBM may have in- 
direct effects on the GABAA receptor complex or may 
be involved in other mechanisms of action (Gordon 
et al., 1991). FBM also has been tested for a possible 
effect on excitatory amino acid receptors. FBM inhib- 
ited N-methyl-D-aspartate (NMDA)- and quisqualate- 
induced seizures in mice but did not significantly 
inhibit MK-801 binding (Sofia et al., 1991). The sig- 
nificance of these results remains to be determined. 
Despite these early studies, the anticonvulsant mech- 
anism of action of felbamate remains unknown. 
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GABAPENTIN 
GBP, 1 -(aminomethyl)-cyclohexaneacetic acid, is a 
cyclic GABA analogue originally designed to mimic 
the stenc conformation of GABA (Schmidt, 1989), to 
have high lipid solubility to penetrate the blood-brain 
barrier, and to be a centrally active GABA agonist with 
potential therapeutic value (Rogawski and Porter, 
1990). GBP has been shown to have anticonvulsant 
activity in a variety of animal seizure models (Bartoszyk 
et al., 1986) and is effective in the treatment of human 
partial and generalized tonic-clonic seizures. 
Despite demonstrated efficacy of GBP against a va- 
riety of seizures, the anticonvulsant mechanism of ac- 
tion is not known. Early research suggested that GBP 
may act on GABAergic neurotransmitter systems be- 
cause it protected mice from tonic extension in chem- 
ical convulsion models using inhibitors of GABA syn- 
thesis (e.g., 3-mercaptopropionic acid, isonicotinic acid, 
semicarbazide) or antagonists acting on the GABAA 
receptor complex (e.g., bicuculline, picrotoxin) (Bar- 
toszyk et al., 1983; Bartoszyk and Reimann, 1985). 
However, subsequent research has not clearly dem- 
onstrated a specific effect of GBP on GABAergic neu- 
rotransmitter systems. Inhibition of monoamine release 
by GBP in electrically stimulated rabbit caudate nu- 
cleus (Reimann, 1983) and rat cortex (Schlicker et al., 
1985) was not modified by GABA, baclofen, or bicu- 
culline, suggesting that GBP did not act on GABAA or 
GABAB receptors. Binding experiments in rat brain 
and spinal cord have shown that GBP has no significant 
affinity for the GABAA- or GABAB-binding sites mea- 
sured by [3H]muscimol and [3H]baclofen displacement, 
respectively. GBP did not significantly inhibit the 
binding of [3H]DZP, had only a weak inhibitory effect 
on the GABA-degrading enzyme GABA-aminotrans- 
ferase, did not elevate GABA content in nerve termi- 
nals, and did not affect the GABA uptake system (Bar- 
toszyk et al., 1986). However, GBP has been shown to 
increase GABA turnover in several regions of rat brain 
(Loscher et al., 1991), and recent research has shown 
that GBP binds to a novel high-affinity site in partially 
purified synaptic plasma membranes from rat neocor- 
tex and is potently displaced by the anticonvulsant drug 
3-isobutyl GABA (Taylor et al., 1993). 
In electrophysiological studies, gabapentin did not 
affect depolarizations elicited by iontophoretic appli- 
cation of GABA on cultured mouse spinal cord neu- 
rons (Taylor et al., 1988; Rock et al., unpublished data). 
In addition, GBP appeared to act by GABA receptor- 
independent mechanisms in studies with rat hippo- 
campal slices (Haas'and Wieser, 1986) and the feline 
trigeminal nucleus (Kondo et al., 199 1). GBP has been 
shown to decrease inhibition evoked by paired-pulse 
orthodromic stimulation of pyramidal neurons in the 
rat hippocampal slice preparation (Dooley et al., 1985; 
Taylor et al., 1988); however, the specific effect of GBP 
is not known. 
GBP protected mice from convulsions caused by 
strychnine, a glycine receptor antagonist, but was un- 
able to displace ['Hlstrychnine in binding studies at 
the highest concentrations tested (Bartoszyk et al., 
1986). Electrophysiological studies showed no effect of 
GBP on the response of spinal cord neurons to ion- 
tophoretically applied glycine (Rock et al., unpublished 
data). 
GBP has been tested in animal seizure models in 
which seizures are induced by administration of excit- 
atory amino acids. GBP prolonged the onset latency 
of clonic convulsions and tonic extension and death 
in mice after the mice were given intraperitoneal in- 
jections of NMDA but not kainic acid or quinolinic 
acid. GBP did not have a clear effect on convulsions 
when those compounds or glutamate was injected into 
the lateral ventricle of rats (Bartoszyk, 1983). Intra- 
peritoneal injections in mice of GBP or the NMDA 
receptor competitive antagonist 3-((*)-2-carboxypi- 
perazin-4-yl)-propyl- 1 -phosphonic acid (CPP) antag- 
onized tonic seizures. The effect of GBP, but not CPP, 
was dose dependently antagonized by the administra- 
tion of serine, an agonist at the glycine receptor on the 
NMDA receptor complex, suggesting an involvement 
of the strychnine-insensitive glycine site of the NMDA 
receptor in the antiepileptic activity of GBP (Oles et 
al., 1990). 
In unpublished studies, GBP reportedly antagonized 
NMDA-induced, but not kainate-induced, depolariza- 
tions in rat thalamic and hippocampal slice prepara- 
tions and antagonized NMDA-induced currents in the 
presence of glycine in cultured striatal neurons, an ef- 
fect that was reversed by the addition of serine or in- 
creased glycine (Chadwick, 1992). Other studies did 
not show a significant effect of GBP on neuronal re- 
sponses to iontophoretic application of glutamate or 
on membrane depolarizations and single-channel cur- 
rents evoked by NMDA with or without coapplication 
of glycine (Kelly et al., 199 1 ). Those results, in part, 
are similar to the findings of others in which GBP had 
no effect on spinal cord neuron depolarizations elicited 
by iontophoretically applied glutamate (Taylor et al., 
1988) or pressure-ejected NMDA (Wamil et al., 1991~). 
In addition, in extracellular recordings from rat hip- 
pocampal slice preparations, GBP had no effect on 
long-term potentiation, making it unlike NMDA re- 
ceptor antagonists (Taylor et al., 1988). 
GBP had no effect on sustained repetitive firing of 
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action potentials in mouse spinal cord neurons (Taylor 
et al., 1988; Rock et al., unpublished data). In other 
experiments using the same neuronal preparation, high 
concentrations of GBP ( 100 p M )  reduced sustained 
repetitive firing of action potentials. After overnight 
exposure of the cultures to GBP, sustained repetitive 
firing of action potentials was reduced by GBP ( 1  p M )  
(Wamil et al., 1991b). The different results of these 
studies done on mouse spinal cord neurons suggest 
that the antiepileptic activity of GBP is not due to in- 
hibition of sustained repetitive firing of sodium action 
potentials. 
Although GBP is most effective in the treatment of 
human partial and generalized tonic-clonic seizures, 
the effect of GBP on absence seizures has been studied 
both in animal models of absence seizures and as add- 
on therapy in patients whose epilepsy is drug resistant. 
In animal studies using pentylenetetrazol-induced 
clonic seizures, GBP protected mice from clonic con- 
vulsions in both the subcutaneous pentylenetetrazol 
test and the intravenous threshold test (Bartoszyk et 
al., 1986). However, in a rat genetic model of absence 
epilepsy, GBP increased EEG spike and wave bursts 
in a dose-dependent manner (Foot and Wallace, 199 1). 
In one human study, GBP reduced >50% of absence 
seizures in half of the patients (Bauer et al., 1989), and 
in another human study, GBP reduced absence seizures 
and generalized spike and wave complexes in patients 
undergoing 24-h EEG monitoring (Rowan et al., 1989). 
In studies of mouse spinal cord neurons, GBP 
blocked responses to Bay K 8644, an agonist at the 
dihydropyridine-binding site of the L-type calcium 
channel (Wamil et al., 1991~).  In other electrophysi- 
ological studies, however, GBP did not significantly 
affect any calcium channel current subtype tested (i.e., 
T, N, or L), suggesting that the basic mechanism of 
action was not on voltage-dependent calcium channels 
(Kelly et al., 1991). 
The results of several studies have not shown GBP 
to have a major effect on ligand- or voltage-gated chan- 
nels. Further study of the high-affinity binding site of 
GBP and the AED 3-isobutyl GABA may contribute 
significantly to our understanding of the mechanism 
of action of GBP. 
LAMOTRIGINE 
LTG, 3,5,-diamino-6-(2,3-dichlorophenyl)- 1,2,4- 
triazine, a phenyltriazine with weak antifolate activity, 
was developed after the observation that PB, PRM, and 
PHT resulted in reduced folate concentrations and that 
folates could induce seizures in experimental animals 
(Reynolds et al., 1966). It was proposed that antifolate 
activity may be related to anticonvulsant activity; how- 
ever, that relationship has not been demonstrated in 
structure-activity studies (Rogawski and Porter, 1990). 
LTG has anticonvulsant activity in several animal sei- 
zure models, including hindlimb extension in maximal 
electroshock and maximal pentylenetetrazol seizures 
in rodents (Miller et al., 1986). LTG has been shown 
to be effective as add-on therapy in the treatment of 
human partial and generalized tonic-clonic seizures. 
The action of LTG on the release of endogenous 
amino acids from rat cerebral cortex slices in vitro has 
been studied. LTG potently inhibited the release of 
glutamate and aspartate evoked by the sodium-channel 
activator veratrine and was much less effective in the 
inhibition of release of acetylcholine or GABA. At high 
concentrations, LTG had no effect on spontaneous or 
potassium-evoked amino acid release. These studies 
suggested that LTG acted at voltage-dependent sodium 
channels, resulting in decreased presynaptic release of 
glutamate (Leach et al., 1986). In radioligand studies, 
the binding of [3H]batrachotoxinin A 20-a-benzoate, 
a neurotoxin that binds to receptor site 2 on voltage- 
dependent sodium channels, was inhibited by LTG in 
rat brain synaptosomes. In electrophysiological studies, 
LTG blocked sustained repetitive firing in cultured 
mouse spinal cord neurons in a dose-dependent man- 
ner at concentrations therapeutic in the treatment of 
human seizures (Cheung et al., 1992). These results 
suggest that the antiepileptic effect of LTG is due to a 
specific interaction at the voltage-dependent sodium 
channel that may result in a preferential decrease in 
presynaptic glutamate release. 
CONCLUSION 
Currently available AEDs appear to have only three 
major mechanisms of action. AEDs that are effective 
against generalized tonic-clonic and partial seizures 
appear to reduce sustained high-frequency repetitive 
firing of action potentials by delaying recovery of so- 
dium channels from inactivation. AEDs that are effec- 
tive against generalized absence seizures appear to re- 
duce low-threshold (T-type) calcium channel current. 
Finally, AEDs that are effective against myoclonic sei- 
zures generally enhance GABAA receptor inhibition. 
Although currently available AEDs have been shown 
to be effective, there clearly are a number of patients, 
especially those with complex partial seizures, whose 
epilepsy is refractory to available AEDs. FBM, LTG, 
and GBP have shown promise in clinical trials and 
may be of some help in managing some patients with 
refractory epilepsy. Although the mechanisms of action 
of those AEDs is unclear, at least GBP and FBM may 
have novel mechanisms of action. Furthermore, it is 
likely that additional new AEDs that are under devel- 
Epilepsia. Vol. 34. Suppl. S, 1993 
AED MECHANISMS OF ACTION s7 
opment will have actions on different neurotransmitter 
receptors or channels. For example, considerable effort 
has been directed toward developing compounds that 
are antagonists of excitatory amino acid transmission. 
It is to be hoped that new AEDs that act on different 
neurotransmitter receptors or channels will permit pa- 
tients whose seizures are currently untreatable to be 
treated pharmacologically. 
To date, approaches to the investigation of the 
mechanisms of action of AEDs have been fairly de- 
scriptive. With the recent development and application 
of new molecular biological techniques to the study of 
CNS function and the cloning of cDNAs for specific 
neurotransmitter receptors and ion channels that are 
targets of AEDs, it may be possible to study in more 
detail the interactions of AEDs with their target recep- 
tors or channels. That investigative research will assist 
in the elucidation of channel and receptor structure 
and perhaps also clarify the interactions of AEDs with 
receptors and channels. Insights gained from such 
studies may be helpful in the design of improved AEDs 
that may act on presently known receptors or channels 
but have more specific or selective actions. 
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